In conclusion, our study indicated that empagliflozin could protect diabetic cardiomyopathy by up-regulating PP2Cm, promoting catabolism of BCAA, and downregulating mTOR/p-ULK1, thereby up-regulating ULK1 and increasing autophagy. Here, ULK1 is linked to diabetic cardiomyopathy.